Izokibep achieves never-before-seen results in Hidradenitis Suppurativa

20 March 2023
acelyrin_big

California, USA-based immunology specialist Acelyrin has announced data from the open label Part A of a Phase IIb/III trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) that demonstrated treatment with its lead candidate izokibep resulted high orders (HiSCR75 and above) of HiSCR response at 12 weeks, including HiSCR100 responses in 33% of participants, claiming these results are better than any seen before.

HS is a chronic, inflammatory skin disease characterized by abscesses, nodules, fistulae, pain, scarring and malodor, all contributing to a devastating impact on quality of life. The data were presented at the American Academy of Dermatology (AAD) Annual Meeting on March 18, 2023.

While the data are in a relatively small number of patients and lack a placebo-controlled arm, the results suggest additional clinical benefits with izokibep's small molecule size and albumin-binding capabilities – two characteristics in common with sonelokimab from Swiss biotech MoonLake (Nasdaq: MLYX) – in improving penetration and alleviating inflammation in harder-to-target tissues in HS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology